rs185392267 — PCSK9 Arg96Cys

Gain-of-function missense variant in PCSK9 that increases intracellular LDL receptor degradation, causing autosomal dominant familial hypercholesterolemia

See your personal result for PCSK9

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

PCSK9 Arg96Cys — A Rare Gain-of-Function Variant Driving Familial Hypercholesterolemia

The PCSK9 protein acts as a master regulator of LDL receptors11 LDL receptors
low-density lipoprotein receptors on the liver surface that clear LDL-cholesterol from the bloodstream. When PCSK9 binds to an LDL receptor, it hijacks the receptor into a lysosomal degradation pathway instead of allowing it to recycle back to the cell surface. Fewer receptors means less LDL clearance, and plasma LDL-cholesterol climbs. The rs185392267 T allele — encoding Arg96Cys22 Arg96Cys
arginine-to-cysteine substitution at amino acid position 96, in the propeptide domain of PCSK9 — is a gain-of-function (GOF) variant that amplifies this degradation activity beyond the normal range, causing autosomal dominant hypercholesterolemia33 autosomal dominant hypercholesterolemia
a hereditary condition where a single copy of the mutant gene is sufficient to cause significantly elevated LDL-cholesterol.

The Mechanism

Wild-type PCSK9 degrades LDL receptors through two routes: an intracellular pathway, where newly synthesized PCSK9 binds LDLR in the trans-Golgi network and routes it directly to lysosomes; and an extracellular pathway, where secreted PCSK9 binds the EGF-A domain44 EGF-A domain
epidermal growth factor-like repeat A domain, the LDLR segment that recognizes LDL at the cell surface and prevents recycling after endocytosis.

The Arg96Cys substitution introduces a cysteine residue into the propeptide/inhibitor domain of PCSK9. Cell-based studies by Elbitar et al. (2018)55 Cell-based studies by Elbitar et al. (2018)
New Sequencing Technologies Help Revealing Unexpected Mutations in Autosomal Dominant Hypercholesterolemia. Scientific Reports 2018 demonstrated that PCSK9-R96C accumulates at higher cellular levels (~60% more total protein than wild-type) but is secreted at a reduced rate (~60% less secretion). Despite reduced secretion, when expressed in HepG2 hepatocyte cells, PCSK9-R96C degrades the LDL receptor to a greater extent than wild-type PCSK9 via the intracellular pathway. The net effect: more LDLR destruction, fewer surface receptors, and less hepatic LDL clearance — driving chronically elevated plasma LDL-C.

The Evidence

Elbitar et al. identified PCSK9-R96C66 Elbitar et al. identified PCSK9-R96C in a French patient carrying a compound heterozygous state alongside a pathogenic APOB variant — the first such combination reported. The patient had severe hypercholesterolemia consistent with an additive effect. Importantly, the paper demonstrated that PCSK9-R96C is a genuine GOF mutation capable on its own of causing autosomal dominant hypercholesterolemia. An earlier cohort study reported R96C in three Danish familial hypercholesterolemia patients with mean untreated total cholesterol of 271.5 ± 46.0 mg/dL and LDL-C of 191.4 ± 34.4 mg/dL, with 2 of 3 patients presenting coronary artery disease.

ClinVar variation 440714 classifies c.286C>T as "conflicting interpretations of pathogenicity": 2 pathogenic, 1 likely pathogenic, and 6 uncertain significance submissions — a reflection of the variant's rarity rather than contradictory functional evidence. The functional cell studies constitute strong mechanistic evidence for pathogenicity.

For PCSK9 GOF mutations as a class, Hopkins et al. (2015)77 Hopkins et al. (2015) found that heterozygous carriers treated with alirocumab88 alirocumab
anti-PCSK9 monoclonal antibody; brand name Praluent achieved 62.5–73% LDL-C reductions. This is mechanistically expected: PCSK9 inhibitors prevent PCSK9 from binding LDLR regardless of whether the PCSK9 carries a GOF mutation, restoring receptor recycling.

Practical Actions

Carriers of Arg96Cys should treat their lipid profile as pharmacologically actionable. First-line therapy is high-intensity statin (atorvastatin 40–80 mg or rosuvastatin 20–40 mg), which reduces hepatic cholesterol synthesis, upregulates LDLR expression, and typically lowers LDL-C by 50–60%. Because statin therapy also transcriptionally upregulates PCSK9 expression, the GOF variant partially blunts statin response compared with LDLR-deficient FH. Adding ezetimibe (10 mg daily) blocks intestinal cholesterol reabsorption and achieves an additional 15–20% LDL-C reduction. If LDL-C remains above the target (<70 mg/dL for high cardiovascular risk; <55 mg/dL for very high risk per 2025 ESC/EAS focused update), a PCSK9 inhibitor (evolocumab or alirocumab) is the next step and is particularly rational here: it directly counteracts the variant's mechanism. Combined statin + ezetimibe + PCSK9 inhibitor can lower LDL-C by 75–80% from baseline. Regular lipid panels, lipoprotein(a) measurement, and cardiovascular imaging (coronary artery calcium score) help stratify individual risk.

Interactions

The Arg96Cys variant is found in the same gene as the well-studied PCSK9 loss-of-function variants rs11591147 (R46L) and rs562556 (E670G), which have the opposite effect — reducing LDLR degradation and lowering LDL-C. A compound heterozygote inheriting one R96C GOF allele alongside a PCSK9 LOF allele in the other copy may have partially attenuated disease severity, though no case is reported. Notably, the Elbitar paper identified the first compound heterozygote combining PCSK9-R96C with an APOB pathogenic variant (rs121918386 class), in whom the additive lipid phenotype was severe — an important clinical scenario where standard FH genetic panels may underestimate disease burden if only one gene is sequenced.

Genotype Interpretations

What each possible genotype means for this variant.

CC No Variant Normal

Common genotype — normal PCSK9 activity and LDL-C clearance

You carry two copies of the reference allele at rs185392267. This is the overwhelmingly common genotype found in more than 99.99% of people globally. Your PCSK9 protein functions within the normal range at this position, and your LDL receptor turnover is not affected by this particular variant.

CT Heterozygous Carrier High Risk

One copy of the Arg96Cys gain-of-function allele — elevated LDL-C and cardiovascular risk

The Arg96Cys substitution occurs in the propeptide/inhibitory domain of PCSK9 (amino acid 96). Unlike some PCSK9 GOF variants that act primarily through enhanced extracellular LDLR binding, R96C acts primarily through an intracellular pathway: the mutant protein accumulates at ~60% higher cellular levels than wild-type but is secreted less efficiently, and when present inside the hepatocyte it drives greater LDLR destruction than normal PCSK9. The net outcome is a reduced number of functional LDL receptors on the liver surface and chronically elevated plasma LDL-C.

As a single-copy (heterozygous) carrier, you retain one wild-type PCSK9 allele producing normal protein, which partially compensates. However, the GOF allele is dominant — the elevated LDLR degradation it drives is not neutralized by the normal allele. The result is intermediate-to-severe LDL elevation that, untreated, carries a substantially increased risk of premature coronary artery disease.

PCSK9 inhibitors (evolocumab, alirocumab) are mechanistically well-matched to this variant: they block PCSK9 protein from binding LDL receptors extracellularly, compensating for the intracellular GOF effect by maximizing recycling of any receptors that do reach the cell surface. Combined statin + ezetimibe + PCSK9 inhibitor typically achieves 75–80% LDL-C reduction, which is sufficient to reach guideline targets for most heterozygous carriers.

TT Homozygous High Risk

Two copies of Arg96Cys — homozygous gain-of-function, likely severe LDL elevation requiring specialist care

Homozygous familial hypercholesterolemia caused by PCSK9 GOF mutations is extraordinarily rare. Unlike homozygous LDLR-deficient FH — where PCSK9 inhibitors are less effective because there are no receptors to rescue — PCSK9 GOF homozygotes may retain residual LDLR expression and could respond to PCSK9 inhibitor therapy, though evidence for R96C specifically is absent.

Standard homozygous FH treatment approaches include: - High-intensity statins (partial effect through non-LDLR pathways and any residual receptor activity) - Ezetimibe for additive intestinal cholesterol reduction - PCSK9 inhibitors — likely to provide benefit given residual receptor function - Lomitapide (microsomal triglyceride transfer protein inhibitor) — reduces hepatic VLDL and LDL production independently of LDLR - LDL apheresis — extracorporeal mechanical removal of LDL particles; often weekly - Emerging RNA-based therapies (inclisiran, which reduces PCSK9 production)

This genotype requires immediate referral to an FH specialist or lipidology centre with experience in homozygous FH management.